Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
- Status
- TERMINATED
- Phase
- PHASE2
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
- Status
- RECRUITING
- Phase
- PHASE2
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Status
- RECRUITING
- Phase
- PHASE3